Compare AbbVie Inc (ABBV) vs Sony Group Corp (SONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Sony Group Corp — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Sony Group Corp trades at $21.19 (market cap $127.11B). The key difference: AbbVie Inc is far larger — about 3.5× Sony Group Corp's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | SONY | |
|---|---|---|
Market Cap | $449.91B | $127.11B |
Sector | Health | Technology |
52-Week High | $261.07 | $30.26 |
52-Week Low | $184.85 | $19.32 |
Enterprise Value | $513.38B | $123.60B |
Dividend Yield | 2.72% | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Sony's stock trades at $21.40, up 2.93% today, with a bullish technical signal from moving averages. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company reported strong 2025 revenue of $12.96 trillion and net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive, with 68.75% recommending buy. Recent news highlights Sony's shift to digital-only game discs by 2028, sparking consumer backlash.
The outlook is cautiously optimistic due to strong analyst support and solid cash flow, but risks include the negative profit margin forecast for 2026 and market reaction to the digital transition. Investors should weigh the company's innovation efforts against execution risks in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
